The report contains ten-year analysis with the following sections
contact us for pricing
Check out our sample pages |
Many companies now available
Search to find companies of interest
read summary of their published patent
the company report contains more information
ucb pharma | 2324 |
ucb biopharma | 696 |
schwarz pharma | 191 |
amgen | 113 |
lts lohmann therapie-systeme | 85 |
ucb | 41 |
biogen idec ma | 30 |
celltech r & d | 28 |
sanol arznei schwarz | 23 |
ucb farchim | 22 |
ucb pharma | 206 |
schwarz pharma | 85 |
medeva | 22 |
celltech r & d | 14 |
sanol arznei schwarz | 11 |
ucb farchim | 11 |
ucb | 6 |
biogen idec ma | 5 |
lts lohmann therapie-systeme | 5 |
amgen | 5 |
ucb biopharma | 154 |
ucb pharma | 66 |
lts lohmann therapie-systeme | 16 |
amgen | 4 |
biogen ma | 2 |
ucb farchim | 1 |
1) eveon; 2) ucb biopharma | 1 |
schwarz pharma | 1 |
darwin discovery | 1 |
ucb | 1 |
Title of patent family (most common patent title) |
Family members |
Filing year |
---|---|---|
sclerostin binding agents | 121 | 2005 |
pharmaceutical composition with synergistic anticonvulsant effect | 68 | 2006 |
prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate | 57 | 2008 |
antibody molecules having specificity for human tumor necrosis factor alpha, and use the… 🛈 | 53 | 2000 |
auto-injector | 53 | 2011 |
systems for administering medication for rheumatoid arthritis patients | 49 | 2008 |
antibody molecules which bind il-17a and il-17f | 49 | 2011 |
2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | 45 | 2000 |
binding proteins, including antibodies, antibody derivatives and antibody fragments, tha… 🛈 | 43 | 2007 |
antibodies specific for human cd22 and their therapeutic and diagnostic uses | 42 | 2002 |